TRK-950

BIOLOGICAL4 trials

Sponsors

Toray Industries, Inc

Conditions

Bladder CancerCholangiocarcinomaColon CancerColorectal CancerEpithelial Ovarian CancerFallopian Tube CancerGastric AdenocarcinomaGastric Cancer

Phase 1

A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors

CompletedNCT02990481

Toray Industries, IncCholangiocarcinoma, Colon Cancer, Locally Advanced or Metastatic Solid Carcinomas

Start: 2017-03-06End: 2019-09-16Updated: 2025-04-16

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

Active, not recruitingNCT03872947

Toray Industries, IncBladder Cancer, Cholangiocarcinoma, Colorectal Cancer +9

Start: 2019-04-26End: 2026-06-30Updated: 2025-08-03

A Study of TRK-950 in Patients With Advanced Solid Tumors

RecruitingNCT05423262

Toray Industries, IncMelanoma, Solid Tumor

Start: 2022-07-06End: 2027-12-01Target: 49Updated: 2026-03-09

Phase 2

A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

RecruitingNCT06038578

Toray Industries, IncGastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

Start: 2023-10-04End: 2026-06-30Target: 146Updated: 2025-08-03

Related Papers

Abstract 5407: Mechanism of CAPRIN-1 membrane localization in cancer and development of TRK-950, a humanized anti-CAPRIN-1 antibody.

Cancer Research2026-04-03

Development and validation of an antidrug antibody assay for TRK-950 using Melon™ gel and SPEAD pretreatment.

2025-04-17

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with Caprin-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2024-06-012 citations

A randomized, multicenter, open-label, phase 2 study of TRK-950 in combination with ramucirumab and paclitaxel as second-line therapy in patients with CAPRIN-1 positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.

Journal of Clinical Oncology2024-01-201 citations

Identification of Membrane-expressed CAPRIN-1 as a Novel and Universal Cancer Target, and Generation of a Therapeutic Anti-CAPRIN-1 Antibody TRK-950

Cancer Research Communications2023-04-1815 citations

Abstract 3923: Identification of membrane-expressed CAPRIN-1 as a novel and universal cancer target and generation of a therapeutic anti-CAPRIN-1 antibody TRK-950

Cancer Research2023-04-04

A phase-Ib study of TRK-950 combined with anticancer treatment regimens in patients with gastric and gastro-esophageal junction (GEJ) cancer.

Journal of Clinical Oncology2023-01-242 citations